The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraldeschi, Roberta, Newman, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034025/
https://www.ncbi.nlm.nih.gov/pubmed/27713292
http://dx.doi.org/10.3390/ph3041122
_version_ 1782317918598463488
author Ferraldeschi, Roberta
Newman, William G.
author_facet Ferraldeschi, Roberta
Newman, William G.
author_sort Ferraldeschi, Roberta
collection PubMed
description Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.
format Online
Article
Text
id pubmed-4034025
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International
record_format MEDLINE/PubMed
spelling pubmed-40340252014-05-27 The Impact of CYP2D6 Genotyping on Tamoxifen Treatment Ferraldeschi, Roberta Newman, William G. Pharmaceuticals (Basel) Review Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy. Molecular Diversity Preservation International 2010-04-15 /pmc/articles/PMC4034025/ /pubmed/27713292 http://dx.doi.org/10.3390/ph3041122 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Ferraldeschi, Roberta
Newman, William G.
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
title The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
title_full The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
title_fullStr The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
title_full_unstemmed The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
title_short The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
title_sort impact of cyp2d6 genotyping on tamoxifen treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034025/
https://www.ncbi.nlm.nih.gov/pubmed/27713292
http://dx.doi.org/10.3390/ph3041122
work_keys_str_mv AT ferraldeschiroberta theimpactofcyp2d6genotypingontamoxifentreatment
AT newmanwilliamg theimpactofcyp2d6genotypingontamoxifentreatment
AT ferraldeschiroberta impactofcyp2d6genotypingontamoxifentreatment
AT newmanwilliamg impactofcyp2d6genotypingontamoxifentreatment

Ejemplares similares